The latest market report published by Credence Research, Inc. “Hospital Infection Prevention and Control Market – Growth, Future Prospects, and Competitive Analysis, 2016 – 2024,” the global hospital infection prevention and control market was valued at US$ 142.6 Mn in 2015, and is expected to reach US$ 245.6 Mn by 2024, expanding at a CAGR of 6.3% from 2016 to 2024.
Browse the full report Hospital Infection Prevention and Control Market – Growth, Future Prospects and Competitive Analysis, and Forecast, 2016 – 2024 at http://www.credenceresearch.com/report/hospital-infection-prevention-and-control-market
The market experts suggest that healthcare associated infections are a costly issue faced by many hospitals across the globe. Hospital acquired infections are type of infections that are observed in patients during the course of receiving treatment for unrelated conditions. According to the World Health Organization (WHO), infectious waste contributes in this way to the risk of nosocomial infections, putting the health of hospital personnel, and patients, at risk. The Centers for Disease Control and Prevention (CDC) statistically suggested that, with approximately 300,000 occurrences each year, surgical site infections (SSIs) are the second most prevalent HAI in the United States, preceded only by urinary tract infections. At a cost of approximately US$ 10 Bn annually, this high incidence of SSIs significantly impacts the U.S. healthcare system, as well as the bottom line of individual hospitals.
The occurrence of nosocomial infections has been observed worldwide in both developed and resource-poor countries. Key factors assisting the growth of hospital infections prevention and control market are rising prevalence of infections, implementation of stringent guidelines associated with hospital infection prevention and control, developing healthcare infrastructure in emerging countries, and rising number of hospitals across the world.
The global hospital infection prevention and control market is segmented by infection type as pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA and others. These are the major types of hospital acquired infections that find the highest prevalence. As sourced from the CDC, ventilator associated pneumonia and surgical site infection are the most common conditions followed by GI infection, UTI, and primary blood stream infection.
Global Hospital Infection Prevention and Control Market are segmented by Product type as Infection Prevention Supplies, Infection Prevention Equipment and Infection Prevention Services. Infection prevention supplies held the largest share in the overall hospital infection prevention and control market.
Based on the therapeutic application type, the global hospital infection prevention and control market is segmented as follows:
Infection Prevention Supplies
Protective Apparel & Textiles
Safety-Enhanced Medical Devices
Medical Waste Disposal Supplies
Infection Prevention Equipment
Other Infection Prevention Equipment
Infection Prevention Services
Other Infection Prevention Equipment
As of the current market scenario, North America formed the largest market for hospital infection prevention and control market due to rising prevalence of the nosocomial infection and stringent regulation followed by the hospitals, clinicians and care givers aligning with regulatory bodies. Asia Pacific is the fastest growing segment with increase in awareness of the healthcare associated infection, rising investment in health care infrastructure, technological advancement and new protocols and programs conducted for infection prevention and control in line with WHO guidelines.
Market Competition Assessment:
Key players in the Hospital Infection Prevention Control market are
3M Company, Ansell Ltd., Becton, Dickinson and Company, Belimed AG, Bemis Company, Inc., B. Braun Melsungen AG, Cantel Medical Corp., Cantel Medical Corp., Covidien plc, Crosstex International, Inc., Danaher Corp., Diversey, Inc., Getinge Group, Johnson & Johnson, Halyard Health, Inc., MMM Group, Matachana Group, Medivators, Inc., Purdue Pharma LP, Sealed Air Corp, Semperit AG Holding, Synergy Health plc, and Terumo Corp.
Browse the full report at http://www.credenceresearch.com/report/hospital-infection-prevention-and-control-market
Key Market Movements:
Hospital acquired infections are a growing issue of preventable disease burden in respect of morbidity and mortality in all countries. Nosocomial infection is major cause of concern for the patient and as well as the health care providers. The rising prevalence of the nosocomial infection is major driving factor for hospital infection and prevention market.
WHO and various others regulatory bodies at regional and national level provide guidelines for hospital infection prevention and control. The significant steps taken to control infection include to identify patients at risk of nosocomial infection, maintaining the hand hygiene, practicing standard precautionary measure to reduce the transmission and applying novel strategies to reduce VAP, CR-BSI, and CAUTI.
In Emerging economies, there is rise in R&D and increase government initiative in health care sector. There has being introduction of key corporate hospital chains, which play major role in driving the growth and the expansion of the healthcare sector. With this rise in the number of hospital increases the chances of nosocomial infection.
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
For Latest Updates @ http://globalindustryresearch.blogspot.com/
Name: Chris Smith
Designation: Global Sales Manager